Appendix to slide34-84: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.

	Years after the first	N	OS		ell Sources, 1991-2020 Years after the first	Ν	OS		Years after the first	N	OS
	transplantation				transplantation				transplantation		
Auto	At transplantation	36,739		Rel-BM	At transplantation	11,948		AML	At transplantation	24,083	
	1 year	27,994	84.0%		1 year	8,577	73.8%		1 year	14,273	63.6%
	5 years	13,055	62.2%		5 years	5,597	58.5%		5 years	6,839	45.8%
	10 years	5,104	51.1%		10 years	3,439	54.6%		10 years	3,082	41.2%
Allo	At transplantation	60,618		Rel-PB	At transplantation	11,929		ALL	At transplantation	12,829	
	1 year	36,694	64.9%		1 year .	6,615	60.9%		1 year	8,569	70.9%
	5 years	18,861	49.2%		5 years	2,791	41.9%		5 years	4,407	51.8%
	10 years	8,905	44.7%		10 years	1,195	36.4%		10 years	2,140	47.4%
				UR-BM	At transplantation	21,051		ATL	At transplantation	2,693	
				OT C DI	1 year	13,210	66.9%	/(IE	1 year	1,152	46.0%
					5 years	7,071	51.3%		5 years	485	31.1%
						3,095	46.4%			166	25.9%
					10 years	3,095	40.4%		10 years	100	23.9%
				UR-PB	At transplantation	962		CML	At transplantation	3,723	
					1 year	557	72.5%		1 year	2,547	71.1%
					5 years	68	55.1%		5 years	1,759	59.0%
					10 years	3	45.0%		10 years	1,111	55.0%
				UR-CB	At transplantation	14,728		MDS	At transplantation	6,577	
					1						
					1 vear	7.731	57.6%		1 vear	3.943	65.7%
					1 year 5 vears	7,731 3.333	57.6% 43.5%		1 year 5 vears	3,943 1.832	65.7% 49.2%
					1 year 5 years 10 years	7,731 3,333 1,170	57.6% 43.5% 39.6%		1 year 5 years 10 years	3,943 1,832 727	65.7% 49.2% 42.6%
Slide37. Survival a	after Transplants for M	N alignant		Slide38. Surviva	5 years 10 years	3,333 1,170	43.5% 39.6%	Slide39. Surviva	5 years 10 years	1,832 727	49.2% 42.6%
	after Transplants for M a and MM/PCD, 1991-	2020		Slide38. Surviva Acute L	5 years 10 years I after Autologous Tra eukemia, 1991-2020 </th <th>3,333 1,170 nsplants fe</th> <th>43.5% 39.6% or s></th> <th></th> <th>5 years 10 years I after Autologous Trai ant Lymphoma, 1991-2</th> <th>1,832 727 nsplants fo</th> <th>49.2% 42.6% or logous></th>	3,333 1,170 nsplants fe	43.5% 39.6% or s>		5 years 10 years I after Autologous Trai ant Lymphoma, 1991-2	1,832 727 nsplants fo	49.2% 42.6% or logous>
Lymphom			OS	Slide38. Surviva Acute L	5 years 10 years I after Autologous Tra	3,333 1,170 nsplants fe Autologou N	43.5% 39.6%		5 years 10 years I after Autologous Tra i	1,832 727 nsplants fo 2020 <autol N</autol 	49.2% 42.6%
	A and MM/PCD, 1991- Years after the first transplantation	2020	OS	Acute L	5 years 10 years I after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation	3,333 1,170 nsplants fe	43.5% 39.6% or s>	Maligna	5 years 10 years I after Autologous Trai ant Lymphoma, 1991-2 Years after the first	1,832 727 nsplants fo	49.2% 42.6% or logous>
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation	-2020 N 21,036		Slide38. Surviva Acute L AML : Age ≤ 15	5 years 10 years I after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation	3,333 1,170 nsplants fe Autologou N 235	43.5% 39.6% or s> OS		5 years 10 years after Autologous Trans ant Lymphoma, 1991-2 Years after the first transplantation At transplantation	1,832 727 nsplants fo 2020 <autol N 223</autol 	49.2% 42.6% or logous> OS
Lymphom	Years after the first transplantation At transplantation 1 year	-2020 N 21,036 13,883	72.8%	Acute L	5 years 10 years I after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year	3,333 1,170 nsplants fe Autologou N 235 204	43.5% 39.6% or s> OS 86.8%	Maligna	5 years 10 years ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year	1,832 727 nsplants fo 2020 <autol N 223 172</autol 	49.2% 42.6% or logous> OS 78.3%
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation	-2020 N 21,036		Acute L	5 years 10 years I after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation	3,333 1,170 nsplants fe Autologou N 235	43.5% 39.6% or s> OS	Maligna	5 years 10 years after Autologous Trans ant Lymphoma, 1991-2 Years after the first transplantation At transplantation	1,832 727 nsplants fo 2020 <autol N 223</autol 	49.2% 42.6% or logous> OS
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years	21,036 13,883 7,043 2,837	72.8% 57.4%	Acute L AML:Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years	3,333 1,170 nsplants fe Autologou N 235 204 145 110	43.5% 39.6% or s> OS 86.8% 64.2%	Maligna NHL : Age ≤ 15	5 years 10 years after Autologous Trans ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years	1,832 727 nsplants fo 2020 <autol N 223 172 138</autol 	49.2% 42.6% or logous> OS 78.3% 70.8%
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	21,036 13,883 7,043 2,837 1,674	72.8% 57.4% 50.0%	Acute L	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472	43.5% 39.6% or s> OS 86.8% 64.2% 61.5%	Maligna	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2%
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year	21,036 13,883 7,043 2,837 1,674 1,316	72.8% 57.4% 50.0% 86.7%	Acute L AML:Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 1 year	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2%	Maligna NHL : Age ≤ 15	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 10 years	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2% 79.2%
Lymphom	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	21,036 13,883 7,043 2,837 1,674	72.8% 57.4% 50.0%	Acute L AML:Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472	43.5% 39.6% or s> OS 86.8% 64.2% 61.5%	Maligna NHL : Age ≤ 15	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2%
Lymphom NHL HL	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years	21,036 13,883 7,043 2,837 1,674 1,316 636 225	72.8% 57.4% 50.0% 86.7% 69.5%	Acute L AML:Age ≤ 15 AML:Age ≥ 16	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2% 79.2% 62.2%
Lymphom NHL HL Other lymphoma /	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation At transplantation	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609	72.8% 57.4% 50.0% 86.7% 69.5% 62.3%	Acute L AML:Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4%	Maligna NHL : Age ≤ 15	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1%
Lymphom NHL HL	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year At transplantation 1 year	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609 364	72.8% 57.4% 50.0% 86.7% 69.5% 62.3%	Acute L AML:Age ≤ 15 AML:Age ≥ 16	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394 321	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4% 81.5%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 10 years	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37 30</autol 	49.2% 42.6% or Iogous> OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1% 86.3%
Lymphom NHL HL Other lymphoma /	a and MM/PCD, 1991- Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation At transplantation	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609	72.8% 57.4% 50.0% 86.7% 69.5% 62.3%	Acute L AML:Age ≤ 15 AML:Age ≥ 16	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37</autol 	49.2% 42.6% or logous> OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1%
Lymphom NHL HL Other lymphoma / type missing	a and MM/PCD, 1991-Years after the firsttransplantationAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 years10 years10 years10 years10 years	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609 364 196 109	72.8% 57.4% 50.0% 86.7% 69.5% 62.3% 69.4% 52.5%	Acute L AML : Age ≤ 15 AML : Age ≥ 16 ALL : Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394 321 230 155	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4% 81.5% 59.7%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16 HL : Age ≤ 15	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37 30 15 8</autol 	49.2% 42.6% or OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1% 86.3% 73.5%
Lymphom NHL HL Other lymphoma /	a and MM/PCD, 1991-Years after the firsttransplantationAt transplantation1 year5 years10 yearsAt transplantation	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609 364 196 109 11,342	72.8% 57.4% 50.0% 86.7% 69.5% 62.3% 69.4% 52.5% 43.9%	Acute L AML:Age ≤ 15 AML:Age ≥ 16	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394 321 230 155 348	43.5% 39.6% Or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4% 81.5% 59.7% 55.4%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37 30 15 8 1,476</autol 	49.2% 42.6% or OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1% 86.3% 73.5%
Lymphom NHL HL Other lymphoma / type missing	a and MM/PCD, 1991-Years after the firsttransplantationAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 yearsAt transplantation1 year5 years10 years10 years10 years10 years10 years	21,036 13,883 7,043 2,837 1,674 1,316 636 225 609 364 196 109	72.8% 57.4% 50.0% 86.7% 69.5% 62.3% 69.4% 52.5%	Acute L AML : Age ≤ 15 AML : Age ≥ 16 ALL : Age ≤ 15	5 years 10 years 1 after Autologous Tra eukemia, 1991-2020 <br Years after the first transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years 10 years	3,333 1,170 nsplants fe Autologou N 235 204 145 110 1,472 1,150 690 337 394 321 230 155	43.5% 39.6% or s> OS 86.8% 64.2% 61.5% 83.2% 67.3% 63.4% 81.5% 59.7%	Maligna NHL : Age ≤ 15 NHL : Age ≥ 16 HL : Age ≤ 15	5 years 10 years After Autologous Tran ant Lymphoma, 1991-2 Years after the first transplantation At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years At transplantation 1 year 5 years 10 years 10 years At transplantation 1 year 5 years 10 years 10 years 10 years	1,832 727 nsplants fo 2020 <autol N 223 172 138 100 15,526 11,060 5,455 2,086 37 30 15 8</autol 	49.2% 42.6% or OS 78.3% 70.8% 70.2% 79.2% 62.2% 53.1% 86.3% 73.5%

Slide40. Survival after Autologous Transplants for MM/PCD, 1991-2020 <Autologous> (Age≥16)

MIM/PCD	MIM/PCD, 1991-2020 <autologous< th=""></autologous<>									
	Years after the first	N	OS							
	transplantation									
MM / PCD	At transplantation	11,011								
	1 year	9,149	93.7%							
	5 years	3,440	65.6%							
	10 years	807	41.9%							

Slide42. Surv	ival after Allogeneic	Transplants for AML,
2044	2020 < Allomonoio>	$(\Lambda a a > 16)$

	rival after Allogeneic Transpl -2020 <allogeneic> (Age≤1</allogeneic>		AML,		vival after Allogeneic Tran 1-2020 <allogeneic> (Age</allogeneic>		r AML,
	Years after the first transplantation	N	OS		Years after the first transplantation	N	OS
Rel-BM	At transplantation	172		Rel-BM	At transplantation	650	
	1 year	117	72.5%		1 year	449	73.6%
	5 years	39	56.5%		5 years	178	54.1%
	10 years	3	55.0%		10 years	9	48.0%
Rel-PB	At transplantation	86		Rel-PB	At transplantation	2,622	
	1 year	58	73.7%		1 year	1,427	62.8%
	5 years	15	53.4%		5 years	385	41.5%
	10 years	1	34.9%		10 years	11	35.2%
UR-BM	At transplantation	131		UR-BM	At transplantation	3,366	
	1 year	99	82.5%		1 year	2,029	67.0%
	5 vears	42	65.8%		5 vears	742	49.5%
	10 years	2	62.9%		10 years	27	44.9%
UR-CB	At transplantation	276		UR-CB	At transplantation	4,051	
	1 year	207	81.2%		1 year	2,037	57.3%
	5 years	82	60.0%		5 years	544	41.5%
	10 years	7	57.2%		10 years	17	35.4%

Slide43. Survival after Allogeneic Transplants for AML, 2011-2020 <HLA-identical Sibling> (Age≤15)

Slide44. Survival after Allogeneic Transplants for AML, 2011-2020 <HLA-identical Sibling> (Age≥16)

Slide45. Survival after Allogeneic Transplants for AML, 2011-2020 <UR-BM> (Age≤15)

2011-20	2011-2020 SHLA-Identical Sibility (Age215)			2011-20	JZU SHLA-IUEIIIICAI SIDI	mg~ (Ag	er 10)	2011-2	020 - 0K-DIVI (Ayesis)	JIVIZ (AYESTS)			
	Years after the first transplantation	Ň	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS		
Standard risk	At transplantation	58		Standard risk	At transplantation	1,262		Standard risk	At transplantation	89			
	1 year	50	91.1%		1 year	951	83.3%		1 year	77	94.1%		
	5 years	8	67.9%		5 years	343	61.0%		5 years	35	80.2%		
	10 years	0			10 years	15	55.9%		10 years	2	76.4%		
Advanced risk	At transplantation	31		Advanced risk	At transplantation	670		Advanced risk	At transplantation	42			
	1 year	16	55.8%		1 year	280	46.2%		1 year	22	58.2%		
	5 years	6	38.4%		5 years	69	26.0%		5 years	7	36.2%		
	10 years	0			10 years	1	19.8%		10 years	0			

	Slide46. Survival after Allogeneic Transplants for AML, 2011-2020 <ur-bm> (Age≥16)</ur-bm>				al after Allogeneic Trans)20 <ur-cb> (Age≤15)</ur-cb>	Slide48. Survival after Allogeneic Transplants for AML, 2011-2020 <ur-cb> (Age≥16)</ur-cb>					
	Years after the first transplantation	Ν	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS
Standard risk	At transplantation 1 year 5 years 10 years	2,258 1,573 601 22	77.7% 60.7% 55.4%	Standard risk	At transplantation 1 year 5 years 10 years	182 164 69 5	94.4% 75.6% 71.7%	Standard risk	At transplantation 1 year 5 years 10 years	1,855 1,171 319 7	72.8% 58.8% 51.5%
Advanced risk	At transplantation 1 year 5 years 10 years	1,105 455 140 5	45.1% 26.8% 23.6%	Advanced risk	At transplantation 1 year 5 years 10 years	94 43 13 2	54.1% 27.8% 27.8%	Advanced risk	At transplantation 1 year 5 years 10 years	2,196 867 225 10	44.3% 27.3% 22.3%

Slide49. Survival after Allogeneic Transplants for ALL, 2011-2020 < Allogeneic> (Age 15)

Slide50. Survival after Allogeneic Transplants for ALL, 2011-2020 < Allogeneic> (Age>16)

2011	-2020 <allogeneic> (Age≤1</allogeneic>	5)		201 [,]	1-2020 <allogeneic> (Age</allogeneic>	e≥16)	
	Years after the first	Ν	OS		Years after the first	N	OS
	transplantation				transplantation		
Rel-BM	At transplantation	216		Rel-BM	At transplantation	366	
	1 year	170	82.5%		1 year	289	84.0%
	5 years	72	66.9%		5 years	113	66.3%
	10 years	4	61.6%		10 years	6	63.8%
Rel-PB	At transplantation	117		Rel-PB	At transplantation	988	
	1 year	58	59.3%		1 year	674	77.7%
	5 years	23	42.7%		5 years	170	55.6%
	10 years	0			10 years	4	50.6%
UR-BM	At transplantation	245		UR-BM	At transplantation	1,630	
	1 year	194	84.9%		1 year	1,134	77.7%
	5 years	85	71.1%		5 years	421	60.8%
	10 years	3	68.0%		10 years	6	51.9%
UR-CB	At transplantation	393		UR-CB	At transplantation	1,208	
	1 year	294	83.1%		1 year	749	71.0%
	5 years	125	70.2%		5 years	236	55.2%
	10 years	3	67.6%		10 years	7	50.5%

Slide51. Survival after Allogeneic Transplants for ALL, 2011-2020 <HLA-identical Sibling> (Age<15)

Slide52. Survival after Allogeneic Transplants for ALL, 2011-2020 <HLA-identical Sibling> (Age≥16) Slide53. Survival after Allogeneic Transplants for ALL, 2011-2020 <UR-BM> (Age≤15)

2011-202	2011-2020 <hla-identical sibling=""> (Ages15)</hla-identical>			2011-20	JZU SHLA-Identical Sibili	iy- (Ay	e≤10)	2011-2	2011-2020 < UR-DIVIZ (Agests)			
	Years after the first transplantation	Ň	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS	
Standard risk	At transplantation	61		Standard risk	At transplantation	725		Standard risk	At transplantation	123		
	1 year	57	96.7%		1 year	595	90.0%		1 year	111	96.6%	
	5 years	31	90.8%		5 years	210	71.5%		5 years	54	87.2%	
	10 years	1	87.5%		10 years	8	69.1%		10 years	1	83.1%	
Advanced risk	At transplantation	68		Advanced risk	At transplantation	194		Advanced risk	At transplantation	122		
	1 year	48	78.3%		1 year	116	65.6%		1 year	83	73.2%	
	5 years	12	52.2%		5 years	25	39.6%		5 years	31	54.8%	
	10 years	1	52.2%		10 years	1	31.2%		10 years	2	52.8%	

	Slide54. Survival after Allogeneic Transplants for ALL, 2011-2020 <ur-bm> (Age≥16)</ur-bm>			Slide55. Survival after Allogeneic Transplants for ALL, 2011-2020 <ur-cb> (Age≤15)</ur-cb>				Slide56. Survival after Allogeneic Transplants for ALL, 2011-2020 <ur-cb> (Age≥16)</ur-cb>			
	Years after the first transplantation	N	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS
Standard risk	At transplantation	1,233		Standard risk	At transplantation	187		Standard risk	At transplantation	777	
	1 year	935	83.8%		1 year	159	91.2%		1 year	551	81.3%
	5 years	368	68.9%		5 years	86	83.9%		5 years	191	68.9%
	10 years	5	57.9%		10 years	2	81.6%		10 years	5	61.6%
Advanced risk	At transplantation	396		Advanced risk	At transplantation	206		Advanced risk	At transplantation	429	
	1 year	199	58.2%		1 year	136	75.6%		1 year	196	52.4%
	5 years	53	34.4%		5 vears	39	57.2%		5 years	44	30.0%
	10 years	1	32.2%		10 years	1	53.8%		10 years	2	30.0%

Slide57. Survival after Allogeneic Transplants for CML, 2011-2020 <Allogeneic> (Age<15)

Slide58. Survival after Allogeneic Transplants for CML, 2011-2020 < Allogeneic> (Age>16)

2011	-2020 <allogeneic> (Age≤1</allogeneic>	5)		2011	1-2020 <allogeneic> (Age</allogeneic>	<u>216)</u>	
	Years after the first	Ν	OS		Years after the first	N	OS
	transplantation				transplantation		
Rel-BM	At transplantation	16		Rel-BM	At transplantation	38	
	1 year	12	75.0%		1 year	31	91.7%
	5 years	9	75.0%		5 years	13	74.4%
	10 years	1	75.0%		10 years	1	67.0%
Rel-PB	At transplantation	2		Rel-PB	At transplantation	151	
	1 year	2	100.0%		1 year	103	79.0%
	5 years	1	100.0%		5 years	30	63.7%
	10 years	1	100.0%		10 years	0	
UR-BM	At transplantation	14		UR-BM	At transplantation	259	
	1 year	12	85.7%		1 year ່	174	77.4%
	5 years	6	78.6%		5 years	68	66.1%
	10 years	1	78.6%		10 years	2	59.2%
UR-CB	At transplantation	8		UR-CB	At transplantation	192	
	1 year	7	100.0%		1 year	119	71.0%
	5 years	3	100.0%		5 years	57	61.7%
	10 years	1	100.0%		10 years	3	52.9%

Slide59. Survival after Allogeneic Transplants for CML, 2011-2020 <HLA-identical Sibling> (Age≥16)

Slide60. Survival after Allogeneic Transplants for CML, 2011-2020 <UR-BM> (Age≥16) Slide61. Survival after Allogeneic Transplants for CML, 2011-2020 <UR-CB> (Age≥16)

2011 201								20112	ULU VOIL UD/ (Aguaid	,	
	Years after the first transplantation	Ν	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS
Standard risk	At transplantation	45		Standard risk	At transplantation	101		Standard risk	At transplantation	52	
	1 year	34	95.0%		1 year	69	81.6%		1 year	31	82.5%
	5 years	16	89.1%		5 years	28	71.8%		5 years	16	79.8%
	10 years	0			10 years	2	71.8%		10 years	0	
Advanced risk	At transplantation	79		Advanced risk	At transplantation	158		Advanced risk	At transplantation	140	
	1 year	60	84.1%		1 year	105	74.8%		1 year	88	67.1%
	5 years	17	60.3%		5 years	40	62.7%		5 years	41	56.4%
	10 years	1	56.5%		10 years	0			10 years	3	44.8%

	rival after Allogeneic Transpl -2020 <allogeneic> (Age≤1</allogeneic>		NDS,		vival after Allogeneic Trans 1-2020 <allogeneic> (Age</allogeneic>		MDS,
	Years after the first transplantation	N	OS		Years after the first transplantation	Ň	OS
Rel-BM	At transplantation	69		Rel-BM	At transplantation	228	
	1 year	56	91.1%		1 year	144	66.4%
	5 years	31	91.1%		5 years	47	48.9%
	10 years	1	88.0%		10 years	0	
Rel-PB	At transplantation	13		Rel-PB	At transplantation	662	
	1 year	7	91.7%		1 year	363	65.5%
	5 years	3	76.4%		5 years	89	48.5%
	10 years	0	•		10 years	1	44.5%
UR-BM	At transplantation	109		UR-BM	At transplantation	1,519	
	1 year	86	93.4%		1 year	911	67.1%
	5 years	37	85.0%		5 years	295	46.6%
	10 years	2	85.0%		10 years	6	38.6%
UR-CB	At transplantation	47		UR-CB	At transplantation	1,060	
	1 year	33	79.9%		1 year	546	59.8%
	5 years	16	69.2%		5 years	145	42.8%
	10 years	0	-		10 years	3	31.6%

Slide64. Survival after Allogeneic Transplants for MDS, 2011-2020 <HLA-identical Sibling> (Age≤15)

Slide65. Survival after Allogeneic Transplants for MDS, 2011-2020 <HLA-identical Sibling> (Age≥16)

Slide66. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-BM> (Age≤15)

2011-202	20 <hla-identical sibling=""></hla-identical>	2011-2020 <hla-identical sibling=""> (Ages15)</hla-identical>			2011-2020 <hla-identical sibling=""> (Age216)</hla-identical>				2011-2020 <ur-bm> (Age≤15)</ur-bm>			
	Years after the first transplantation	Ň	OS		Years after the first transplantation	N	OS		Years after the first transplantation	Ν	OS	
Standard risk	At transplantation	45		Standard risk	At transplantation	198		Standard risk	At transplantation	78		
	1 year	38	91.0%		1 year	139	76.1%		1 year	68	97.4%	
	5 years	21	91.0%		5 years	48	64.0%		5 years	31	91.3%	
	10 years	0			10 years	1	64.0%		10 years	1	91.3%	
Advanced risk	At transplantation	8		Advanced risk	At transplantation	336		Advanced risk	At transplantation	27		
	1 year	7	87.5%		1 year	191	63.3%		1 year	16	88.9%	
	5 years	5	72.9%		5 years	58	44.4%		5 years	6	76.2%	
	10 years	0			10 years	0			10 years	1	76.2%	

Slide67. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-BM> (Age≥16)

Slide68. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-CB> (Age≤15)

Slide69. Survival after Allogeneic Transplants for MDS, 2011-2020 <UR-CB> (Age≥16)

2011-20	2011-2020 <ur-ым> (Age216)</ur-ым>				2011-2020 < UR-CB> (Age>15)				2011-2020 < OR-CB> (Age=16)				
	Years after the first transplantation	Ν	OS		Years after the first transplantation	N	OS		Years after the first transplantation	N	OS		
Standard risk	At transplantation	561		Standard risk	At transplantation	21		Standard risk	At transplantation	334			
	1 year	370	72.4%		1 year	15	81.0%		1 year	184	64.8%		
	5 years	137	53.5%		5 years	9	73.6%		5 years	51	47.9%		
	10 years	1	46.3%		10 years	0			10 years	2	31.0%		
Advanced risk	At transplantation	927		Advanced risk	At transplantation	21		Advanced risk	At transplantation	716			
	1 year	526	63.9%		1 year	15	79.2%		1 year	359	57.4%		
	5 years	157	42.3%		5 years	5	62.5%		5 years	93	40.4%		
	10 years	5	34.3%		10 years	0			10 years	1	32.3%		

	ival after Allogeneic Transpla -2020 <allogeneic> (Age≤1§</allogeneic>		NHL,	Slide71. Survival after Allogeneic Transplants for NHL, 2011-2020 <allogeneic> (Age≥16)</allogeneic>					
	Years after the first transplantation	Ň	OS		Years after the first transplantation	Ń	OS		
Rel-BM	At transplantation	26		Rel-BM	At transplantation	137			
	1 year	17	72.0%		1 year	81	61.5%		
	5 years	7	72.0%		5 years	35	51.7%		
	10 years	1	72.0%		10 years	6	51.7%		
Rel-PB	At transplantation	19		Rel-PB	At transplantation	766			
	1 year	9	52.6%		1 year	322	48.9%		
	5 years	3	36.1%		5 years	105	37.7%		
	10 years	0	•		10 years	2	31.8%		
UR-BM	At transplantation	33		UR-BM	At transplantation	645			
	1 year	18	67.3%		1 year	362	62.8%		
	5 years	6	55.9%		5 years	159	49.7%		
	10 years	0			10 years	7	46.7%		
UR-CB	At transplantation	45		UR-CB	At transplantation	900			
	1 year	28	72.0%		1 year	391	48.5%		
	5 years	10	72.0%		5 years	150	39.0%		
	10 years	0			10 years	1	36.9%		

Slide73. Survival after Allogeneic Transplants for NHL, 2011-2020 <UR-BM> (Age≤15)

	vival after Allogeneic Transpl -2020 <hla-identical p="" sibling<=""></hla-identical>			Slide73. Survival after Allogeneic Transplants for NHL, 2011-2020 <ur-bm> (Age≤15)</ur-bm>				Slide74. Survival after Allogeneic Transplants for NHL, 2011-2020 <ur-bm> (Age≥16)</ur-bm>				
	Years after the first transplantation	Ň	OS		Years after the first transplantation	Ν	OS		Years after the first transplantation	N	OS	
1CR	At transplantation	103		1CR	At transplantation	6		1CR	At transplantation	152		
	1 year	78	83.8%		1 year	6	100.0%		1 year	105	76.5%	
	5 years	31	67.3%		5 years	0			5 years	47	62.2%	
	10 years	4	60.1%		10 years	0	•		10 years	1	62.2%	
2CR	At transplantation	47		2CR	At transplantation	6		2CR	At transplantation	75		
	1 year	34	78.4%		1 year	3	66.7%		1 year	55	83.0%	
	5 years	17	76.1%		5 years	3	66.7%		5 years	23	65.9%	
	10 years	0			10 years	0			10 years	0		
>=3CR	At transplantation	18		>=3CR	At transplantation	1		>=3CR	At transplantation	43		
	1 year	16	94.1%		1 year	0			1 year	28	69.1%	
	5 vears	3	73.5%		5 years	0			5 years	16	60.6%	
	10 years	0			10 years	0			10 years	1	60.6%	
1PR	At transplantation	52		1PR	At transplantation	4		1PR	At transplantation	61		
	1 year	36	74.2%		1 year	1	33.3%		1 year	38	70.9%	
	5 years	16	57.6%		5 years	1	33.3%		5 years	13	50.0%	
	10 years	2	54.0%		10 years	0			10 years	2	50.0%	
2PR	At transplantation	58		2PR	At transplantation	1		2PR	At transplantation	71		
	1 year	32	61.3%		1 year	0			1 year	40	65.9%	
	5 years	15	52.7%		5 years	Ō			5 years	21	53.3%	
	10 years	1	52.7%		10 years	0			10 years	1	53.3%	
NIR	At transplantation	215		NIR	At transplantation	15		NIR	At transplantation	243		
	1 year	83	40.4%		1 year	8	70.1%		1 year	96	43.8%	
	5 years	26	29.1%		5 years	2	56.1%		5 vears	39	33.3%	
	10 years	1	23.1%		10 years	0	·		10 years	2	28.2%	

	<u>-2020 <ur-cb> (Age≤15)</ur-cb></u>			-	<u>1-2020 <ur-cb>_(Age≥16)</ur-cb></u>		00
	Years after the first transplantation	N	OS		Years after the first transplantation	Ν	OS
1CR	At transplantation	13		1CR	At transplantation	143	
	1 year	9	76.2%		1 year	86	67.8%
	5 years	4	76.2%		5 vears	33	56.4%
	10 years	0			10 years	0	
2CR	At transplantation	5		2CR	At transplantation	79	
	1 year	4	100.0%		1 year	41	62.8%
	5 years	1	100.0%		5 vears	20	52.2%
	10 years	0			10 years	0	-
>=3CR	At transplantation	2		>=3CR	At transplantation	27	
	1 year	2 2	100.0%		1 year	19	74.1%
	5 years	1	100.0%		5 years	12	69.1%
	10 years	0			10 years	0	
2PR	At transplantation	6		1PR	At transplantation	102	
	1 year	6 5	83.3%		1 year	51	56.6%
	5 years	0			5 years	18	53.1%
	10 years	0			10 years	0	
NIR	At transplantation	19		2PR	At transplantation	82	
	1 year	8	55.4%		1 year	33	45.5%
	5 years	4	55.4%		5 years	10	37.3%
	10 years	0			10 years	0	
				NIR	At transplantation	467	
					1 year	161	37.4%
					5 years	57	27.3%
					10 years	1	24.0%

Slide77. Survival after Autologous Tran PCD, 2011-2020 <autologous></autologous>	•	/ MM	Slide78.
	1.130=.01		
Years after the first	N	OS	

Slide78. Survival after Allogeneic Transplants for MM / PCD. 2011-2020 <Allogeneic> (Age≥16)

PCD, 2	2011-2020 <autologous></autologous>	(Age≥16)		PCD), 2011-2020 <allogeneic></allogeneic>	(Age≥16)	
	Years after the first	Ν	OS		Years after the first	N	OS
	transplantation				transplantation		
MM / PCD	At transplantation	7,167		Rel-BM	At transplantation	4	
	1 year	5,819	95.3%		1 year	2	50.0%
	5 years	1,655	72.3%		5 years	0	
	10 years	32	52.7%		10 years	0	
				Rel-PB	At transplantation	31	
					1 year	15	51.6%
					5 years	5	38.3%
					10 years	0	
				UR-BM	At transplantation	24	
					1 year	12	54.2%
					5 years	2	23.0%
					10 years	0	
				UR-CB	At transplantation	17	
					1 year	4	23.5%
					5 years	1	11.8%
					10 years	0	

	val after Autologous Trans 2011-2020 <autologous></autologous>		MM /		ival after Allogeneic Trans 2011-2020 <allogeneic></allogeneic>	plants for (Age≥16)	
-	Years after the first	N	OS		Years after the first	N	OS
	transplantation				transplantation		
CR / sCR	At transplantation	1,459		CR / sCR	At transplantation	16	
	1 year	1,187	97.9%		1 year	10	68.8%
	5 years	285	78.7%		5 years	0	
	10 years	5	58.2%		10 years	0	
GPR	At transplantation	2,200		VGPR	At transplantation	9	
	1 year	1,788	96.6%		1 year	7	77.8%
	5 years	508	73.0%		5 years	1	31.1%
	10 years	8	49.0%		10 years	0	-
R	At transplantation	2,508		PR	At transplantation	21	
	1 year	2,070	95.0%		1 year	10	52.4%
	5 years	634	69.9%		5 years	6	31.4%
	10 years	12	50.3%		10 years	0	
	At transplantation	229		SD	At transplantation	9	
	1 year	183	91.2%		1 year	2	22.2%
	5 years	50	55.2%		5 years	0	
	10 years	3	50.1%		10 years	0	
D / Rel	At transplantation	161		PD / Rel	At transplantation	17	
	1 year	95	67.2%		1 year	2	11.8%
	5 years	15	28.3%		5 years	1	5.9%
	10 years	0			10 years	0	

	rival after Allogeneic Transpl -2020 <allogeneic> (Age≤1</allogeneic>		AA,	Slide82. Survival after Allogeneic Transplants for AA, 2011-2020 <allogeneic> (Age≥16)</allogeneic>					
	Years after the first transplantation	Ň	OS		Years after the first transplantation	Ň	OS		
Rel-BM	At transplantation	136		Rel-BM	At transplantation	197			
	1 year	117	97.0%		1 year	167	92.2%		
	5 years	56	96.1%		5 years	73	87.9%		
	10 years	2	96.1%		10 years	4	85.8%		
Rel-PB	At transplantation	7		Rel-PB	At transplantation	79			
	1 year	5	71.4%		1 year	51	74.3%		
	5 years	3	71.4%		5 years	16	67.9%		
	10 years	0			10 years	1	67.9%		
UR-BM	At transplantation	137		UR-BM	At transplantation	274			
	1 year ່	112	95.3%		1 year	204	81.0%		
	5 years	55	92.8%		5 years	87	74.3%		
	10 years	4	92.8%		10 years	4	74.3%		
UR-CB	At transplantation	21		UR-CB	At transplantation	135			
	1 year	20	100.0%		1 year	84	70.7%		
	5 years	8	100.0%		5 years	34	69.7%		
	10 years	1	100.0%		10 years	3	69.7%		

	l after Allogeneic Transpl 20 <allogeneic> (Age≤1</allogeneic>	AA,	Slide84. Survival after Allogeneic Transplants for AA, 2011-2020 <allogeneic> (Age≥16)</allogeneic>					
	Years after the first transplantation	N	OS		Years after the first transplantation	N	OS	
HLA-identical	At transplantation	111		HLA-identical	At transplantation	216		
Sibling	1 year	96	96.3%	Sibling	1 year	178	88.7%	
U	5 years	49	95.2%	Ū	5 years	77	83.2%	
	10 years	2	95.2%		10 years	4	83.2%	
UR-BM	At transplantation	137		UR-BM	At transplantation	274		
	1 year	112	95.3%		1 year	204	81.0%	
	5 years	55	92.8%		5 vears	87	74.3%	
	10 years	4	92.8%		10 years	4	74.3%	
UR-CB	At transplantation	21		UR-CB	At transplantation	135		
	1 year	20	100.0%		1 year	84	70.7%	
	5 years	8	100.0%		5 years	34	69.7%	
	10 years	1	100.0%		10 years	3	69.7%	